Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
Chad A. Bousman, James M. Stevenson, Laura B. Ramsey, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 1, pp. 51-68
Open Access | Times Cited: 175

Showing 1-25 of 175 citing articles:

Cost-effectiveness of pharmacogenomic-guided treatment for major depression
Shahzad Ghanbarian, Gavin Wong, Mary Bunka, et al.
Canadian Medical Association Journal (2023) Vol. 195, Iss. 44, pp. E1499-E1508
Open Access | Times Cited: 28
Pharmaco-Multiomics: A New Frontier in Precision Psychiatry
Dhoha Dhieb, Kholoud Bastaki
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1082-1082
Open Access | Times Cited: 1
Changes in S‐Citalopram Plasma Concentrations Across Pregnancy and Postpartum
Catherine S. Stika, Michael J. Avram, Alfred L. George, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review
Chad A. Bousman, Abdullah Al Maruf, Diogo Marques, et al.
Psychological Medicine (2023) Vol. 53, Iss. 16, pp. 7983-7993
Open Access | Times Cited: 19
An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean
Aimeé Salas-Hernández, Macarena Galleguillos, Matías Carrasco, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting
Amy Turner, Charity Nofziger, Bronwyn Ramey-Hartung, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 6, pp. 1220-1237
Open Access | Times Cited: 15
The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank
Win Lee Edwin Wong, Chiara Fabbri, Benjamin Laplace, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1277-1277
Open Access | Times Cited: 14
Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals
Kristine Tveit, Monica Hermann, Roy M. Nilsen, et al.
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 3, pp. 435-444
Open Access | Times Cited: 5
From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
Qamar Shubbar, Aminah Alchakee, Khaled Walid Issa, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis
Yundan Liao, Yutao Sun, Jing Guo, et al.
EBioMedicine (2024) Vol. 104, pp. 105165-105165
Open Access | Times Cited: 5
Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial
Lei Xu, Liyin Li, Qiutang Wang, et al.
Journal of Affective Disorders (2024) Vol. 359, pp. 117-124
Open Access | Times Cited: 4
Polypharmacy and pharmacogenomics in high-acuity behavioral health care for autism spectrum disorder: A retrospective study
Sheldon R. Garrison, Sophie A. Schweinert, Matthew W. Boyer, et al.
Research Square (Research Square) (2025)
Closed Access
When Patients Present With Direct-to-Consumer Pharmacogenomic Test Results
Roseann S. Donnelly, Houriya Ayoubieh, Elizabeth Kudron, et al.
Mayo Clinic Proceedings (2025) Vol. 100, Iss. 2, pp. 197-203
Closed Access
The Use of Pharmacogenomics in Mental Health
Trina Walker, Crystal Dodson, Chad A. Bousman
Nursing Clinics of North America (2025)
Closed Access
Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey
Catherine M. Lockhart, Michael Manolakis
Journal of Managed Care & Specialty Pharmacy (2025) Vol. 31, Iss. 1-b Suppl, pp. S15-S19
Closed Access
Impact of CYP2D6 polymorphisms on the pharmacokinetics, efficacy, and safety of tamsulosin therapy in patients with benign prostatic hyperplasia
Sh. P. Abdullaev, Sh. P. Abdullaev, М Н Шатохин, et al.
Meditsinskiy sovet = Medical Council (2025), Iss. 23, pp. 244-254
Open Access
Impact and Enablers of Pharmacogenetic-Informed Treatment Decisions—A Longitudinal Mixed-Methods Study Exploring the Patient Perspective
Anna Bollinger, Melissa Semedo Fortes, Henriette E. Meyer zu Schwabedissen, et al.
Pharmacy (2025) Vol. 13, Iss. 1, pp. 14-14
Open Access
The Assessment of the Safety Profile of Selective Serotonin Reuptake Inhibitors Versus Other Antidepressants: Drug–Drug Interaction Insights from EudraVigilance
Carmen Maximiliana Dobrea, Claudiu Morgovan, Adina Frum, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1208-1208
Open Access
CYP2D6 Genetic polymorphisms impact on tamsulosin efficacy and safety in patients with benign prostatic hyperplasia
Sh. P. Abdullaev, М Н Шатохин, I. V. Sychev, et al.
Drug Metabolism and Personalized Therapy (2025)
Closed Access
Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients
Jens Andreas Sarömba, Julian Peter Müller, Jolanta Tupiec, et al.
British Journal of Clinical Pharmacology (2025)
Open Access
A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder
Alessio Squassina, Pasquale Paribello, Marco Pinna, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111292-111292
Open Access
Implementing Pharmacogenomics Clinical Decision Support: A Comprehensive Tutorial on how to Integrate the Epic Genomics Module
Bradley R. Hall, Eda Eken, Larisa H. Cavallari, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access
Interactions between the intestinal microbiota and drug metabolism – Clinical implications and future opportunities
Dianne Ford
Biochemical Pharmacology (2025), pp. 116809-116809
Open Access
Association Between CYP2D6 Genotypes and Serum Concentrations of Mirtazapine and Mianserin
Kristine Hole, Espen Molden
Basic & Clinical Pharmacology & Toxicology (2025) Vol. 136, Iss. 4
Closed Access
Screening of RNA methyltransferase NSP16 inhibitors against SARS-CoV-2 coronavirus and study of related mechanisms
Xinyue Fan, Dangui Zhou, Chonghe Xu, et al.
American Journal of Translational Research (2025) Vol. 17, Iss. 2, pp. 1237-1250
Closed Access
Page 1 - Next Page

Scroll to top